AUA 2023热点速递：免疫治疗在膀胱癌新辅助治疗中的进展

详细信息

收稿日期: 2023-05-15

刊出日期: 2023-06-06

Highlights from AUA 2023: progress of immunotherapy in the neoadjuvant therapy of bladder cancer

- Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China

More Information

Received Date: 15 May 2023

Publish Date: 06 June 2023

摘要: 吉西他滨(Gemcitabine，G)和顺铂(Cisplatin，C)的联合治疗方案(GC方案)是肌层浸润性膀胱癌(muscle invasive bladder cancer，MIBC)术前新辅助的标准治疗，近年来免疫治疗的兴起，为GC方案不耐受或抵抗的患者提供了新的治疗希望。4月28日—5月1日，2023年美国泌尿外科协会(AUA)年会在美国芝加哥盛大召开。膀胱癌领域免疫治疗的多项临床研究公布了最新的研究结果。本文就这些最新的临床研究结果做简要介绍。
- 膀胱癌 /
- 免疫治疗 /
- 化疗 /
- 新辅助治疗
Abstract: The combination therapy of gemcitabine (G) and cisplatin (C) (GC regimen) is a standard treatment for muscle invasive bladder cancer (MIBC) preoperative neoadjuvant therapy. The rise of immunotherapy in recent years has provided new therapeutic hope for patients with intolerance or resistance to GC regimen. From April 28th to May 1st, the 2023 American Urological Association (AUA) Annual Meeting was held in Chicago, USA. Many clinical studies on immunotherapy in the field of bladder cancer have published the latest research results. This article provides a brief introduction to the latest clinical research results.
- bladder cancer /
- immunotherapy /
- chemotherapy /
- neoadjuvant therapy

[1]	Rosenberg JE, Ballman KA, Halabi S, et al. Randomized Phase Ⅲ Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601(Alliance)[J]. J Clin Oncol, 2021, 39(22): 2486-2496. doi: 10.1200/JCO.21.00286
[2]	Fujita N, Momota M, Horiguchi H, et al. Impact of neoadjuvant chemotherapy-induced acute kidney injury on oncological outcomes in patients who underwent radical cystectomy: a multicenter retrospective study[J]. J Urol, 2023, 209(4S): e243.
[3]	Rose K, Bandini M, Huelster H, et al. Neoadjuvant pembrolizumab shows promise as effective systemic therapy prior to radical cystectomy for cisplatin-ineligible muscle invasive bladder cancer[J]. J Urol, 2023, 209(4S): e777.
[4]	Nocera L, Bandini M, Basile G, et al. Chemotherapy vs immunotherapy as neoadjuvant therapies in cisplatin-eligible patients undergoing radical cystectomy for muscle invasive bladder cancer[J]. J Urol, 2023, 209(4S): e1126.
[5]	Funt SA, Lattanzi M, Whiting K, et al. Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase Ⅱ Trial[J]. J Clin Oncol, 2022, 40(12): 1312-1322.
[6]	Mouzannar A, Whiting K, Ostrovnaya I, et al. Perioperative outcomes of radical cystectomy following neoadjuvant gemcitabine, cisplatin and atezolizumab[J]. J Urol, 2023, 209(4S): e983.